Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar Carnero Contentti

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Neurologia I Neurochirurgia Polska|August 23, 2016
Commentary on painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorderEdgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2017
Letter re "Is pruritus an indicator of aquaporin-positive neuromyelitis optica?"Edgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2023
Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin AmericaEdgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2024
Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitisEdgar Carnero Contentti
Multiple Sclerosis and Related Disorders|April 13, 2020
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challengeEdgar Carnero Contentti, Jorge Correa
Drug Design, Development and Therapy|October 14, 2022
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple SclerosisEdgar Carnero Contentti, Jorge Correale
Therapeutic Advances in Neurological Disorders|August 5, 2025
Induction of immune tolerance in NMOSD and MOGADJorge Correale, Edgar Carnero Contentti
Multiple Sclerosis and Related Disorders|April 2, 2026
Limited availability of live CBA for MOG-IgG testing and its consequences for the diagnosis and treatment of MOGAD in Latin American countriesVinícius Boldrini, Edgar Carnero Contentti
Expert Opinion on Emerging Drugs|February 23, 2025
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorderEdgar Carnero Contentti, Jorge Correale
Expert Opinion on Emerging Drugs|September 10, 2020
Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosisEdgar Carnero Contentti, Jorge Correale
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Neurologia I Neurochirurgia Polska|August 23, 2016
Commentary on painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorderEdgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2017
Letter re "Is pruritus an indicator of aquaporin-positive neuromyelitis optica?"Edgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2023
Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin AmericaEdgar Carnero Contentti
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2024
Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitisEdgar Carnero Contentti
Multiple Sclerosis and Related Disorders|April 13, 2020
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challengeEdgar Carnero Contentti, Jorge Correa
Drug Design, Development and Therapy|October 14, 2022
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple SclerosisEdgar Carnero Contentti, Jorge Correale
Therapeutic Advances in Neurological Disorders|August 5, 2025
Induction of immune tolerance in NMOSD and MOGADJorge Correale, Edgar Carnero Contentti
Multiple Sclerosis and Related Disorders|April 2, 2026
Limited availability of live CBA for MOG-IgG testing and its consequences for the diagnosis and treatment of MOGAD in Latin American countriesVinícius Boldrini, Edgar Carnero Contentti
Expert Opinion on Emerging Drugs|February 23, 2025
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorderEdgar Carnero Contentti, Jorge Correale
Expert Opinion on Emerging Drugs|September 10, 2020
Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosisEdgar Carnero Contentti, Jorge Correale
Pageof 15